{
    "id": 29141,
    "fullName": "NF1 G2392*",
    "impact": "nonsense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NF1 G2392* results in a premature truncation of the Nf1 protein at amino acid 2392 of 2839 (UniProt.org). R2392* has been associated with resistance to lorlatinib in culture (PMID: 30322862), but has not been biochemically characterized and therefore, its effect on Nf1 protein function is unknown (PubMed, Sep 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 13404,
                    "pubMedId": 30322862,
                    "title": "Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30322862"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4763,
        "geneSymbol": "NF1",
        "terms": [
            "NF1",
            "NFNS",
            "VRNF",
            "WSS"
        ]
    },
    "variant": "G2392*",
    "createDate": "12/28/2018",
    "updateDate": "09/30/2019",
    "referenceTranscriptCoordinates": {
        "id": 184032,
        "transcript": "NM_001042492",
        "gDna": "chr17:g.31343120G>T",
        "cDna": "c.7174G>T",
        "protein": "p.G2392*",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15502,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) restored sensitivity to Lorbrena (lorlatinib) in neuroblastoma cells harboring ALK R1275Q and an acquired NF1 G2392* mutation in culture (PMID: 30322862).",
            "molecularProfile": {
                "id": 31076,
                "profileName": "ALK R1275Q NF1 G2392*"
            },
            "therapy": {
                "id": 7655,
                "therapyName": "Lorlatinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13404,
                    "pubMedId": 30322862,
                    "title": "Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30322862"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15501,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NF1 G2392* was identified as a potential resistance mutation in a neuroblastoma cell line harboring ALK R1275Q that acquired resistance to Lorbrena (lorlatinib) in culture (PMID: 30322862).",
            "molecularProfile": {
                "id": 31076,
                "profileName": "ALK R1275Q NF1 G2392*"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 769,
                "name": "neuroblastoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 13404,
                    "pubMedId": 30322862,
                    "title": "Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30322862"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31075,
            "profileName": "NF1 G2392*",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31076,
            "profileName": "ALK R1275Q NF1 G2392*",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 184033,
            "transcript": "XM_005257983",
            "gDna": "chr17:g.31343120G>T",
            "cDna": "c.7174G>T",
            "protein": "p.G2392*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 184032,
            "transcript": "NM_001042492",
            "gDna": "chr17:g.31343120G>T",
            "cDna": "c.7174G>T",
            "protein": "p.G2392*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}